‘Transformational' new breast cancer drug could halt the growth of tumours
A new drug has been shown to halt the growth of certain breast cancer tumours, potentially delaying the need for chemotherapy, according to a new study.
The Serena-6 trial found that camizestrant is effective in stopping cancer cells from using hormones to grow. One professor described the drug as representing "a pivotal moment in breast cancer care".
Scientists said the trial marked the first global study demonstrating that early detection of cancer resistance through blood tests can significantly benefit patients.
The study focused on patients with hormone-positive, HER2-negative breast cancer, which accounts for approximately 70 per cent of all cases. The results indicated that patients treated with camizestrant experienced a 56 per cent reduction in cancer progression compared to those receiving standard therapies.
Doctors used a blood test to identify changes in the cancer's DNA, which signal the potential failure of current treatments. Upon detecting these signs, some patients were administered camizestrant, while others continued with their standard treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1 per cent stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Finextra
28 minutes ago
- Finextra
Deep Dive: Wise – Building a World of Money Without Borders: By Sam Boboev
Wise (formerly TransferWise) has quietly become one of fintech's biggest success stories, transforming how people and businesses send money across borders. From humble startup origins in 2011, Wise now moves over £145 billion internationally each year for 15+ million customers – at a fraction of the cost charged by banks. In doing so, Wise saved its users an estimated £2 billion in fees in FY2025 alone. It's a rare fintech that's both fast-growing and profitable, pursuing a bold mission encapsulated in its slogan: 'Money without borders – instant, convenient, transparent and eventually free.' This deep dive explores why Wise matters today – covering the massive market it's tackling, its journey and products, the technology and regulatory infrastructure under its hood, its recent financial performance, competitive landscape, and what customers and leadership are saying. A Massive Market Ripe for Disruption Moving money internationally has long been notorious for high costs and hassle. Over £22 trillion crosses borders each year, projected to reach £28 trillion by 2027 as globalization drives more migration, remote work, and global commerce. By Wise's own 2025 estimate, the number may be as high as £32 trillion annually. Historically, this market was dominated by big banks and legacy remittance providers relying on an antiquated correspondent banking network. International transfers often meant 'expensive, slow and inefficient service, reliant on outdated infrastructure,' as Wise's 2023 report bluntly puts it. Banks and incumbents like Western Union layered on fees and hidden exchange rate markups – profiting from customers' lack of transparency. The result: sending money abroad could cost 5-8% in fees (often not obvious upfront) and take days to arrive. Wise was founded to change this status quo. Its vision of 'Money Without Borders' is about making moving money 'as cheap, fast, and convenient as sending an email,' in the words of its co-founder. Wise's core innovation was using technology and clever account structures to eliminate intermediaries and hidden fees, giving users the real mid-market exchange rate and charging only a low upfront fee. As we'll see, this strategy is forcing the industry to evolve. Today, many fintechs and even banks are racing to offer cheaper, easier cross-border payments – yet traditional banks remain Wise's primary competitors, still handling the majority of cross-currency transactions. A growing field of digital challengers (from neobanks like Revolut to PayPal's Xoom and others) are also carving out niches. But Wise has a head start in scale, efficiency, and trust – built over a decade of singular focus on solving this problem. From Startup to Public Company Wise's origin story is a personal one. In 2011, two Estonian friends living in London – Kristo Käärmann and Taavet Hinrikus – grew frustrated with the 'massive problem' of bank fees on international transfers. They started TransferWise that year to help people send money abroad at the true exchange rate. The concept resonated: by 2014, having raised a $58 million Series C to expand globally, TransferWise launched in the US and Australia. The company hit major milestones quickly. It reached its first £1 billion transferred (cumulative) in 2014, and by 2017 was profitable with over £1 billion being moved every month through its platform – a rarity in fintech. Importantly, Wise also became an innovator in financial infrastructure early on. In 2016 it gained direct access to the UK's Faster Payments network (the first tech company to do so), showing a knack for working with regulators to improve speed and cost. Over time, TransferWise broadened its offerings beyond person-to-person remittances. In 2016 it launched its first business accounts for SMEs to send money internationally on better terms. By 2018 it rolled out a borderless multi-currency account and debit Mastercard, enabling customers to hold money in multiple currencies and spend it via card in different countries with low fees. The company's global footprint also expanded: it opened offices around the world (10 offices by 2019, including a European hub in Belgium to navigate Brexit) and set up an Asia-Pacific hub in Singapore in 2017. In 2021, reflecting its broadened mission, TransferWise rebranded to 'Wise.' That same year, Wise went public via a direct listing on the London Stock Exchange – notably, London's largest tech listing ever at the time. The listing valued Wise at ~$11 billion, signaling its arrival as a major fintech player. Today, Wise is truly international: over 6,500 employees ('Wisers') across 20+ offices serve customers in 170+ countries. Yet the company insists it's 'still solving only a fraction of the problem'. As CEO Kristo Käärmann wrote, 'Twelve years ago we set out to solve the massive problem people and businesses face in sending money around the world… While we're nowhere near mission complete, 16 million people and businesses are now helping us get closer every day.' In the next sections, we'll examine how Wise is attempting to fulfill that mission through its products and underlying infrastructure. --------- Source: Wise Annual Reports FY2023–FY2025; product pages and blog; CEO and executive statements from Wise reports; and Wise investor reports highlighting key metrics. All data and quotes are from official Wise materials. Disclaimer: Fintech Wrap Up aggregates publicly available information for informational purposes only. Portions of the content may be reproduced verbatim from the original source, and full credit is provided with a "Source: [Name]" attribution. All copyrights and trademarks remain the property of their respective owners. Fintech Wrap Up does not guarantee the accuracy, completeness, or reliability of the aggregated content; these are the responsibility of the original source providers. Links to the original sources may not always be included. For questions or concerns, please contact us at
Daily Mail
8 hours ago
- Daily Mail
How to tell if your crusty brown skin patch is something sinister... and when you should call the doctor - by top skin expert AENONE HARPER-MACHIN
As the human body's largest organ, it's no surprise that an endless number of things can go wrong with your skin. There are the lumps and bumps that can appear out of nowhere, the myriad of shapes and colours of moles, freckles, warts and patches of skin which may turn darker or become dry and crusty.
Daily Mail
9 hours ago
- Daily Mail
Parents warned to limit their children's screen time, as research finds youngsters glued to smartphones and tablets have smaller brains and lower IQs
Parents are being warned to limit children's screen time after a study found it could lead to them having smaller brains and lower intelligence. Scientists found children who watched television and used smartphones, tablets and computers had, on average, lower IQs and less intracranial volume (ICV) – a marker for brain size. In contrast, children who exercised in their spare time were likely to be more intelligent and had a larger brain volume, according to the research. The study used databases from across Europe that contained information from thousands of children on IQ, screen use and physical exercise. This was analysed to establish whether there was any link between leisure time habits, intelligence and ICV – the total space within the skull which is used as a proxy for the maximum size of the brain. Larger ICV has been linked to superior intelligence. The researchers, based in China, say their results provide further evidence that excessive screen time has a lifelong impact on children's brain development. 'These findings highlight the critical need to manage and regulate children's media use while also promoting increased physical activity,' they wrote in the journal Developmental Cognitive Neuroscience. The study comes as children's screen time use has rocketed in recent years. The average amount of time British children aged five to 15 spend on screens rose from nine hours a week in 2009 to 15 hours a week in 2018, according to a House of Commons education committee report from last year. While there can be benefits, including building friendships and improving learning, negative effects include online bullying, exposure to violence and pornography, lower levels of physical activity and eye strain. Sir Cary Cooper, a psychology professor at the University of Manchester, said: 'Children are using these devices and they are not learning social and non-verbal skills that we pick up from interacting, face-to-face, with other people.'
